[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Imperial College London\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":703},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,136,0,25,[9,49,81,107,129,164,191,215,238,263,300,328,355,382,411,434,465,489,515,544,570,590,615,642,674],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100647154","emg-directed-virtual-reality-training-for-motor-stroke-rehabilitation-100647154",false,"NCT07705256","EMG-Directed Virtual-Reality Training for Motor Stroke Rehabilitation","Pilot Study of EMG-Directed Virtual-Reality Experience Training for Motor Stroke Rehabilitation","Inclusion Criteria:\n\n* Aged 18 or over\n* Cognitive status that would permit for use \u002Fsupported use of intervention device and engagement in protocol related trainings\u002Fassessment. To be indicated by treating clinician at point of screening, formal capacity assessment to be conducted as appropriate. Refer to easy read patient information sheet (PIS) and training materials to support all patients presenting with specific cognitive and\u002For communication needs.\n* (We do not wish to exclude patients with cognitive impairment as this would limit the heterogeneity of our sample and generalizability of our findings, given the prevalence of cognitive impairment in stroke patients.)\n* Stroke diagnosis (can be first or subsequent stroke, unilateral haemorrhagic or ischemic) 2 weeks max post stroke at time of recruitment.\n* Can communicate in English, that is, sufficient for completion of intervention and outcome measures. A speech and language therapist (SLT) will be consulted if necessary to ensure all reasonable accommodations are made to support participation.\n* UL motor deficit post stroke (bilateral\u002Funilateral) (according to National Institutes of Health Stroke Score (NIHSS) item 5), distal UL power \\\u003C1 \u002F5 on the Oxford Rating Scale (Medical Research Council Manual Muscle Testing scale).\n\nExclusion Criteria:\n\n* Patients already enrolled an interventional neuro rehabilitation trial.\n* Patients enrolled in clinical trials that contraindicate co-enrolment.\n* Patients presenting with unstable medical conditions\u002Fmedical contraindications as determined by treating medical consultant (these patients may be approached at a later date should their condition improve).\n* Those registered blind\u002Fwith uncompensated\u002Funcorrected visual deficits, including severe neglect that prevents them from being able to focus on visually provided feedback.\n* Behavioural\u002Faffective dysfunction which could influence the ability of the person to engage with the research protocol and\u002For pose risk to the participating researchers (in circumstances such as follow-up community visits).\n* Other concomitant neurological disorders affecting upper extremity motor function (Multiple Sclerosis, Spinal Cord Injury, Brachial Plexus or Radial Nerve Injury).\n* Unremitting arm, wrist or hand pain at rest (Numeric Pain Rating Scale \\> 4). Consumption of caffeine 2 hours prior to assessment (assessment will be postponed to a later time).\n* Pre-existing UL impairment with known and significant disruption to range of motion, motor or functional performance (fracture, arthritic changes, other known musculoskeletal problems). Or pre-modified Rankin Score \\> 2.\n* Skin condition apparent on the ventral UE such that might place participant at risk of irritation in the context of repeated physical contact (such as that associated with the intervention).\n* Subsequent MRI that fails to confirm stroke\n* Chronic stroke patients whose stroke occurred in excess of 2.5 years ago\n* Patients whose cognitive impairment prevents them from following instructions","ALL","18 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is testing whether rehabilitation using muscle activity signals can help improve arm and hand movement in people after stroke or spinal cord injury.\n\nIn the main study, participants will use a virtual-reality feedback system that is controlled by surface electromyography (EMG). Surface EMG uses sensors placed on the skin to detect muscle activity. The feedback will help participants practise upper limb movements during rehabilitation.\n\nA related sub-study will run alongside the main study. In this sub-study, functional electrical stimulation will also be used to help activate muscles during training.\n\nThe study will assess whether these rehabilitation approaches improve upper limb function. It will also explore whether changes in biological or movement-related markers are linked with recovery.",[27,28],"Stroke","Spinal Cord Injuries (Complete and Incomplete)",[30,31,32,33,34,35],"Stroke rehabilitation","upper limb rehabilitation","EMG biofeedback","motor recovery","neurorehabilitation","spinal cord injury rehabilitation","NOT_YET_RECRUITING","2026-08-17",{"date":39,"type":40},"2026-08-18","ACTUAL",{"date":42,"type":21},"2026-07-27",{"date":44,"type":21},"2027-11-27",{"name":46,"class":47},"Imperial College London","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100652254","childrens-intensive-care-outcomes-and-health-inequities-a-mixed-methods-study-of-social-determinants-in-paediatric-intensive-care-in-england-100652254","NCT07771179","Children's Intensive Care Outcomes and Health Inequities: A Mixed Methods Study of Social Determinants in Paediatric Intensive Care in England","Learning About Inequities and Outcomes for childreN in Intensive Care and Understanding Barriers Families Face - a Mixed Methods Study","LION-CUB","Parents\u002FCarers\n\nInclusion Criteria:\n\n* Parent or carer of a child admitted to paediatric intensive care at one of the participating sites: Great Ormond Street Hospital, Birmingham Children's Hospital, St Mary's Hospital, or Royal Manchester Children's Hospital.\n* Aged 18 years or over.\n* Able to provide informed consent.\n* Approached no earlier than 48 hours after the child's admission to PICU.\n* Where the child has died, parents\u002Fcarers will be approached between 6 and 12 weeks following the death.\n* Parents\u002Fcarers who do not speak English may be included, with interviews conducted using a professional interpreter where required.\n\nExclusion Criteria:\n\n* Individuals unable to provide informed consent.\n* Families of children with ongoing safeguarding concerns at the time of potential recruitment.\n* Families who are actively involved in a formal complaint process against the hospital at the time of recruitment.\n* Parents\u002Fcarers approached within 48 hours of PICU admission.\n* Bereaved parents\u002Fcarers approached outside the 6-12 week bereavement window.\n\nHealthcare professionals\n\nInclusion Criteria:\n\n* Healthcare professionals aged 18 years or over who either:\n\n  * work in a paediatric intensive care unit, or\n  * are involved in referring children to paediatric intensive care, at one of the four participating sites.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n\\- Individuals unable to provide informed consent.",{"count":58,"type":21},40,"OBSERVATIONAL","This mixed methods study aims to understand how factors such as ethnicity, deprivation, language, and access to healthcare affect outcomes for children admitted to paediatric intensive care (PICU).\n\nThe main questions it aims to answer are:\n\n* Why are some children more likely to be admitted to paediatric intensive care, or to have worse outcomes once they are there, depending on their ethnicity or background?\n* At what points in a child's healthcare journey could earlier support or intervention make a difference?\n\nThe first part of the study will involve interviewing parents and carers of children admitted to intensive care and health care professionals working in or referring children to intensive care. The second part of the study will be an analysis of existing NHS data.\n\nParticipants will have an interview with a researcher lasting 45 minutes to an hour.",[62],"Paediatric Intensive Care",[64,65,66,67,68,69,70,71,72,73],"health equity","social determinants of health","ethnicity","racism","deprivation","Health inequities","Mixed methods","Qualitative research","Socioeconomic factors","Paediatric intensive care","2026-08-14",{"date":39,"type":40},{"date":77,"type":21},"2027-04",{"date":79,"type":21},"2031-07",{"name":46,"class":47},{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":48},"100650808","transthoracic-ultrasound-for-descending-aortic-aneurysms-100650808","NCT07752654","TransThoracic Ultrasound for Descending Aortic Aneurysms","Feasibility, Accuracy and Reproducibility of Ultrasound in Aneurysms of the Descending Thoracic Aorta","THORUS","Inclusion Criteria:\n\n* Patients with diagnosed AAA or other vascular condition attending the vascular scanning department for routine ultrasound and confirmed healthy DTA (Control group).\n* Patients with known DTAA (including Type B dissection) or patients who had TEVAR previously (Case group).\n* Patients who have had CT as part of their standard of care.\n* Patients able to tolerate the scan (Lying in supine position).\n* Adults aged 18 or over.\n* Willing to provide consent.\n\nExclusion Criteria:\n\n* Patient under 18 years of age.\n* Previous thoracic surgery or body deformity (severe kyphosis, scoliosis, pleural effusion or chest wall trauma).\n* Patients without previous imaging of the thoracic aorta.\n* Life expectancy \\\u003C2 years.\n* Pregnant Women.\n* Patients unwilling to provide consent or unable to comply with study requirements.\n* Patients too frail to travel to routine outpatient appointments.\n* Inability to attend the appointment due to time constraints or other commitments.\n* Although rare, ultrasound contraindications as described in the scanning protocol are also exclusion criteria.",true,{"count":91,"type":21},60,"The goal of this observational study is to assess the applicability of non-invasive ultrasound in aneurysms of the descending thoracic aorta.\n\nThe main question it aims to answer is:\n\nWhat is the feasibility of Ultrasound to visualise the Descending Thoracic Aorta, and can this imaging modality accurately measure the maximum size of aneurysms and residual sacs with acceptable reproducibility?\n\nParticipants are having their diagnosis confirmed or excluded by conventional imaging techniques (CT scans). Participants receive exactly the same standard of care regardless of their participation. The study offers an additional ultrasound scan, and the results will be compared with previous imaging.",[94,95,96,97,98],"Descending Aortic Aneurysm","Ultrasound","Accuracy","Feasibility","Reproducibility","2026-08-03",{"date":101,"type":40},"2026-08-07",{"date":103,"type":21},"2026-09-07",{"date":105,"type":21},"2028-04-03",{"name":46,"class":47},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100649660","phase-2-myocardial-metabolic-flux-in-pulmonary-arterial-hypertension-100649660","NCT07737522","Myocardial Metabolic Flux in Pulmonary Arterial Hypertension","Myocardial Metabolic Flux in Patients With Pulmonary Arterial Hypertension (PAH) in Response to GLP-1 Agonist Therapy: a Physiological Study Using 31-Phosphorus MR Spectroscopy","Inclusion Criteria:\n\n\\- 1. Diagnosis of Group 1 PAH confirmed by right heart catheterisation under the National Pulmonary Hypertension Service, Royal Brompton Hospital, part of GSTT Foundation Trust 2. Age over 18, less than 85 years 3. Able to give informed consent 4. On a stable dose of PAH-specific therapies (e.g., ERA, PDE5i) for at least 3 months.\n\n5\\. Clinically justified prescription of GLP-1 agonist Semaglutide based on following criteria: BMI \\> 30 or BMI \\> 27 with at least one cardiovascular co-morbidity (systemic hypertension, diabetes, pre-diabetes, COPD, atrial fibrillation, dyslipidaemia, sleep disordered breathing)\n\nExclusion Criteria:\n\n* • 1. Pregnancy\n\n  * 2\\. Myocardial infarction within the previous 3 months\n  * 3\\. Contraindications to MRI: Pacemakers, metallic implants, or severe claustrophobia.\n  * 4\\. Severe renal impairment: eGFR \\\u003C 15ml\u002Fmin\u002F1.73m.\n  * 5\\. Current use of SGLT2 inhibitors or GLP-1 agonist therapy (which significantly alter fuel substrate preference) or insulin therapy that cannot be held for the fasting scan","85 Years",{"count":116,"type":21},32,[118],"PHASE2","The rationale for this study is that GLP-1 agonist treatment is likely to influence myocardial substrate utilisation, changing the predominant source of metabolic energy within the heart to a more energetically efficient form. This is represented by a surrogate for improved mitochondrial efficiency with reduction in myocardial lactate levels (produced by inefficient myocardial glycolysis, prevalent in the ventricles of patients with pulmonary hypertension), which can be measured by 31P-magnetic resonance spectroscopy (31P-MRS).",[121],"Pulmonary Arterial Hypertension",{"date":123,"type":40},"2026-07-30",{"date":125,"type":21},"2026-10-01",{"date":127,"type":21},"2029-04-01",{"name":46,"class":47},{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":138,"conditions":139,"keywords":147,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},"100647926","breath-research-narrow-validation-for-gastrointestinal-cancer-detection-100647926","NCT07714538","Breath Research Narrow Validation for Gastrointestinal Cancer Detection","BRAVE","Inclusion Criteria:\n\nAdult participants ≥ 18 years old who meet at least one of the following criteria\n\nColorectal arm:\n\n1. Cancer: Histologically-confirmed CRC\\*\n2. Control: Non-specific abdominal symptoms with normal or benign colonoscopy findings\n\nPancreatic arm:\n\n1. Cancer: Histologically-confirmed PDAC\\*\n2. Control: Non-specific abdominal symptoms with a radiologically-normal pancreas\n\nOesophagogastric arm:\n\n1. Cancer: Histologically-confirmed OGC\\*\n2. Control: Non-specific abdominal symptoms with normal or benign upper gastrointestinal endoscopy findings\n\nOesophageal squamous arm:\n\n1. Cancer: Histologically-confirmed OSCC\\*\n2. Control: Non-specific abdominal symptoms with normal or benign upper gastrointestinal endoscopy findings\n\nLiver arm:\n\n1. Cancer: Histologically- or radiologically-confirmed HCC or CCC\\*\n2. Control: Non-specific abdominal symptoms with a radiologically-normal liver\n\n   * Patients with suspected cancer (e.g. based on imaging) but who do not have histological confirmation prior to participating in the study may still be recruited and followed up to determine whether or not a diagnosis of cancer was subsequently confirmed.\n\nExclusion Criteria:\n\n* Patients who have already received chemotherapy, radiotherapy or surgery for their cancer\n* History of another cancer (other than non-melanoma skin cancers) within three years\n* Participants with co-morbidities preventing breath collection\n* Unable or unwilling to provide informed consent\n* (For Oesophagogastric arm only): Allergies to any of the constituents of the nutrient drink including glucose, glycerol, iron sulphate, Maltodextrin (Corn, Potato), Xanthan Gum, Potassium Chloride, tyrosine, phenylalanine, and glutamic acid\n* (For Colorectal arm only): Participants receiving bowel prep in the previous 7 days",{"count":137,"type":21},1000,"The investigators of this study are developing a simple breath test to help detect gastrointestinal (gut) cancers earlier, including cancers of the oesophagus (food pipe), stomach, pancreas, liver and bowel. These cancers often cause non-specific symptoms that are similar to benign conditions, making early diagnosis difficult. Delays between the onset of symptoms and referral for a diagnostic test such as an endoscopy or a scan, can allow the cancer to progress.\n\nThe breath test detects small molecules called volatile organic compounds (VOCs) that are released in exhaled breath. Some of these VOCs are strongly associated with these cancers and may help identify high-risk patients who require urgent investigation.\n\nIn practice, patients who come to their GP with concerning symptoms will be offered the breath test. If the test is positive, patients can be referred promptly for a diagnostic test, while those with a negative result can be reassured and offered re-testing if symptoms persist. Earlier diagnosis could improve access to curative treatment while reducing unnecessary invasive investigations.\n\nPrevious studies have identified a panel of VOCs that appear to distinguish patients with gastrointestinal cancers from those without cancer. This study aims to confirm these findings in a new group of participants to determine whether the same biomarkers can be reliably identified.\n\nParticipants will provide a breath sample, usually before a hospital procedure they are already scheduled to undergo, and complete a short questionnaire about their medical history and medications. Some participants will also be asked to drink a nutritional supplement before providing a second breath sample. The results will help determine whether the breath test is reliable enough for further clinical evaluation",[140,141,142,143,144,145,146],"Oesophageal Squamous Cell Carcinoma","Oesophageal Adenocarcinoma","Gastric Adenocarcinoma","Pancreatic Ductal Adenocarcinoma (PDAC)","Cholangiocarcinoma","Hepatocellular Carcinoma (HCC)","Colorectal Adenocarcinoma",[148,149,150,151,152,153,154],"Early Detection","Volatile Organic Compunds","Oesophageal Cancer","Gastric Cancer","Colorectal Cancer","Liver Cancer","Pancreatic Cancer","2026-07-21",{"date":157,"type":40},"2026-07-23",{"date":159,"type":21},"2026-07-20",{"date":161,"type":21},"2028-08-02",{"name":46,"class":47},6,{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":190},"100501937","physiological-vs-right-ventricular-pacing-outcome-trial-evaluated-for-bradycardia-treatment-protect-hf-100501937","NCT05815745","\"Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment\" (PROTECT-HF)","Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment","PROTECT-HF","We will recruit patients who are referred for clinically indicated pacemaker implantation\n\nInclusion Criteria:\n\n1\\. Adults aged over 18 with left ventricular ejection fraction \\>35% and one or more of the following guideline based ventricular pacing indications:\n\n1. Permanent or intermittent 3rd degree AV block\n2. Permanent or intermittent Mobitz type II AV block\n3. First Degree AV block with a pacing indication\n4. Slow chronic Atrial Fibrillation or Proposed AV node ablation\n5. Bifascicular block with a pacing indication\n6. Trifascicular block with a pacing indication\n7. Wenckebach with a pacing indication\n\nExclusion Criteria:\n\n1. Patients who are likely to only need occasional ventricular pacing, i.e. those with isolated sick sinus syndrome.\n2. Pregnant women.\n3. Unable to provide informed consent.\n4. Those with comorbidity leading to a life expectancy \\\u003C1year.",{"count":173,"type":21},2600,[24],"The PROTECT-HF multi-centre randomised controlled trial will compare two different pacing approaches for treating patients with slow heart rates. In it the investigators will compare a long-standing standard approach for pacing; right ventricular pacing, with a new form of pacing, physiological pacing (His and Left bundle area pacing) in 2600 patients.\n\nPatients will be allocated at random to receive either right ventricular pacing or physiological pacing. Endpoint measurements will be undertaken at baseline, and at six-monthly intervals post-randomisation. Treatment allocation will be blinded to the endpoint assessor and the patient.\n\nRecruitment and pacemaker implantation will be carried out at each participating centre. The primary analysis will be intention to treat. The investigators will also perform an on-treatment analysis.\n\n2048 patients are needed to detect the expected effect size with 85% power. A total of 2600 patients will be recruited to allow for patient drop-out and crossover.\n\n500-patient sub-study will assess within patient, and between groups, echocardiographic changes over a 24-month period to try and improve mechanistic understanding of PICM (Pacing Induced Cardiomyopathy).",[177,178,179,180,181],"Bradycardia","Pacing","Right Ventricular Pacing","His Bundle Pacing","Left Bundle Branch Area Pacing","RECRUITING",{"date":184,"type":40},"2026-07-22",{"date":186,"type":40},"2023-06-05",{"date":188,"type":21},"2031-06-04",{"name":46,"class":47},45,{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":89,"sex":17,"minAge":18,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":214},"100623501","phase-1-development-of-a-controlled-human-infection-model-for-assessment-of-sars-cov-2-omicron-subvariants-100623501","NCT07397455","Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants","COVHIC003","Inclusion Criteria:\n\n* The study informed consent form has been signed and dated by the participant and the Investigator\n* Adults age between 18 and 50 years inclusive (at the time of enrolment)\n* Evidence of having had at least one COVID-19 vaccine, with the last vaccination at least 3 months before enrolment\n* Positive serology for SARS-CoV-2 at (pre)screening\n* Sero-suitable as defined by having serum and\u002For nasal antibody titres less than a pre-defined cut-off of a defined assay(s) which will be specified in a separate SOP and based on accumulating antibody data\n* People of child-bearing potential (POCBP) must be willing and able to use contraception as described in the study protocol from 2 weeks before the scheduled date of viral challenge until the end discharge from quarantine.\n\nNegative urine pregnancy tests will be required at screening and on day 0 prior to inoculation. On admission to the quarantine unit a negative serum beta human chorionic gonadotropin (β-hCG) is required\n\n* Male participants who are willing to use one of the contraception methods described in the study protocol, from the time of the date of viral challenge until the end of quarantine\n* Agree to abstain from sexual activity or use effective contraception from the start of treatment with Paxlovid until 7 days after completing treatment with Paxlovid should they receive it\n* In good health with no history of clinically significant medical conditions (as described in Exclusion criteria) that would interfere with participant safety, as defined by medical history, physical examination and routine laboratory tests, ECG, and Chest X-Ray and determined by the Investigator at an admission evaluation\n* Participants will have a documented medical history either prior to entering the study and\u002For following medical history review with the study physician at screening\n* Willing to be registered with The Over-Volunteering Protection Service (TOPS)\n* Willing and able to commit to participation in the study.\n\nExclusion Criteria:\n\n* History or evidence of any clinically significant or currently active cardiovascular, (including thromboembolic events), respiratory, dermatological, gastrointestinal, endocrine, haematological, hepatic, immunological, rheumatological, metabolic, urological, renal, neurological, psychiatric illness\n* Any significant abnormality altering the anatomy or function of the nose or nasopharynx in a substantial way (including loss of or alterations in smell or taste), a clinically significant history of epistaxis (large nosebleeds) within the last 3 months, nasal or sinus surgery within 6 months of inoculation\n* Clinically-active, symptomatic rhinitis (including hay fever) or history of severe rhinitis, or seasonal allergic rhinitis likely to be active at the time of inclusion into the study and\u002For requiring regular nasal corticosteroids on an at least weekly basis, within 30 days of admission to quarantine\n* History of anaphylaxis and\u002For a history of severe allergic reaction or significant intolerance to any food or drug, as assessed by the Investigator\n* Significant history or presence of drug or alcohol misuse (exceeding \\>28 units a week)\n* Current use of any drugs taken through the nasal or inhaled route including recreational drugs\n* Psychiatric illness including participants with a history of depression and\u002For anxiety with associated severe psychiatric comorbidities, for example psychosis.\n* Current active smokers, equivalent to \\>5 cigarettes per week, including use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g., gum, patch) or electronic cigarettes. • Participants who have smoked ≥5 pack years at any time \\[5 pack years is equivalent to one pack of 20 cigarettes a day for 5 years\\]) or the equivalent amount of nicotine if using alternative forms. • Ex-smokers who have smoked \\\u003C5 pack years at any time must not of have regularly smoked in the last 3 months equivalent to \\>5 cigarettes per week.\n* Family history of 1st degree relative aged 50 years or less with sudden cardiac or unexplained death\n* Personal or Family History of unexpectedly severe COVID-19, adverse response to any other viral disease e.g. Guillain-Barré, or a family history (described as a 1st degree relative) with clotting disorders\n* A total body weight of ≤ 45kg and a Body Mass Index (BMI) ≤18 kg\u002Fm2 and ≥28 kg\u002Fm2. The upper limit of BMI may be increased to ≤ 30kg\u002Fm2 at the Investigator's discretion, in the case of physically fit muscular individual\n* Venous access deemed inadequate for the phlebotomy demands of the study.\n* Any clinically significant abnormal finding on screening biochemistry, haematology and microbiology blood tests or urinalysis i.e. grade 1 lab abnormalities or above apart from minor deviations which are clinically acceptable and approved by the Investigator\n* A forced expiratory volume in 1 second (FEV1) and a forced vital capacity (FVC) \\\u003C80% of predicted value calculated using ATS\u002FERS guidance. Spirometry will be performed only if the mMRC dyspnoea score ≥1 or if clinically indicated\n* Twelve-lead ECG recording with clinically relevant abnormalities as judged by the Investigator\n* History of, or currently active symptoms suggestive of upper or lower respiratory tract infection (including reduced sense of taste and smell, raised body temperature and\u002For persistent cough) within 4 weeks prior to viral challenge\n* Presence of cold-like symptoms and\u002For fever (defined as participant presenting with a temperature reading of \\>37.9ºC) on Day -2, Day -1 and\u002For pre-challenge on Day 0.\n* Evidence of any respiratory pathogens (on Respiratory PCR from upper respiratory tract sample) prior to challenge virus inoculation on admission to the quarantine unit\n* Evidence of a live vaccine within 60 days prior to the planned date of viral challenge, a non-live vaccine within 30 days prior to the planned date of viral challenge or intention to receive any vaccination(s) before the day 28 follow-up visit. (NB. No travel restrictions applied after the Day 28 Follow-up visit).\n* Receipt of blood or blood products, or loss (including blood donations) of 550 mL or more of blood during the 3 months prior to the planned date of viral challenge or planned during the 3 months after the final visit.\n* Medications\n\n  1. Use of any medication or product (prescription or over-the-counter), for symptoms of hay fever, nasal congestion or respiratory tract infections or dermatitis\u002Feczema including the use of regular nasal or medium-high potency dermal corticosteroids, antibiotics and First Defence™ (or generic equivalents) within 7 days prior to the planned date of viral challenge apart from those described in Table 7, Permitted Medication or agreed by the Investigator.\n  2. Receipt of any investigational drug within 3 months prior to the planned date of viral challenge.\n  3. Receipt of three or more investigational drugs within the previous 12 months prior to the planned date of viral challenge.\n  4. Receipt of systemic (intravenous and\u002For oral) glucocorticoids or antiviral drugs known to have activity against respiratory viruses within 6 months prior to the planned date of viral challenge (excluding Pre-Exposure Prophylaxis (PrEP)).\n  5. Over the counter medications (e.g., paracetamol or ibuprofen) where the dose taken over the preceding 7 days prior to the planned date of viral challenge had exceeded the maximum permissible 24-hour dose (e.g., \\>4g per day of paracetamol over the preceding week).\n  6. Chronically used medications, including any medication known to be a moderate\u002Fpotent inducer or inhibitor of cytochrome P450 enzymes, within 21 days prior to the planned date of viral challenge, except for those agreed by the Investigator.\n  7. Participants who have received any systemic chemotherapy agent, immunoglobulins, or other cytotoxic or immunosuppressive drugs at any time.\n  8. Concurrent use of medications strongly contraindicated for use with Paxlovid unless confirmed alternative rescue therapy will be available to the site at the time of enrolment\n* Prior participation in another human viral challenge study in the preceding 6 months taken from the date of viral challenge in the previous study to the date of expected viral challenge in this study. The participant must also have completed the follow up visit requirements of the previous viral challenge study\n* Any invasive nasal sampling procedure in the month before date of expected viral challenge in this study (excluding study tolerance test or routine tests for COVID-19)\n* Participant is mentally or legally incapacitated in the opinion of the Investigator\n* POCBP who:\n\n  1. Are breastfeeding within 6 months of study commencement, or\n  2. Had been pregnant within 6 months prior to the study, or\n  3. Had a positive pregnancy test at any point during screening or prior to inoculation with challenge virus\n* Those in close domestic contact (i.e. sharing a household with, caring for, or daily face to face contact) with children under 2 years, the elderly (\\>65 years), immunosuppressed persons, or those with chronic respiratory disease\n* Anyone who works on the study (e.g. a delegated study nurse) or in close proximity to the study at the sponsor organisation, participating trial sites or any contract research organisations involved in this study.\n* Anyone who is first degree related to, or resides with, anyone who is a delegated member of the research team at a study site\n* Any other reason that the Investigator considered made the participant unsuitable to participate\n* Participants with no knowledge of their family history","50 Years",{"count":200,"type":21},38,[202],"PHASE1","COVHIC003 is a human infection challenge study in which healthy adults aged 18-50 previously vaccinated with an approved COVID-19 vaccine will be administered a SARS-CoV-2 Omicron EG.5.1 variant given by drops in the nose. The aim is to achieve breakthrough upper-respiratory infection in a proportion of volunteers with mild or no illness, providing information on the course of Omicron infection and the immune response in vaccinated people. This study will establish an optimised challenge dose and model that can then be used to evaluate new vaccines and treatments in follow-on trials. Participants will stay in a quarantine unit for approximately 10-12 days, depending on infection status, and will be closely monitored with regular swabs, blood tests and symptom assessments throughout their stay. They will be followed up by the study team for 6 months after being discharged. This study is sponsored by Imperial College London and forms part of the MUSICC project which is led by Imperial College London and co-funded by the European Union's Horizon Europe Programme and the Coalition for Epidemic Preparedness Innovations (CEPI). Quarantine will take place at specialist facilities in Oxford or at the Royal Free Hospital in London.",[205],"SARS-CoV-2 (COVID-19)","2026-07-16",{"date":208,"type":40},"2026-07-17",{"date":210,"type":40},"2026-07-10",{"date":212,"type":21},"2028-12-31",{"name":46,"class":47},5,{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":89,"sex":17,"minAge":223,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":4},"100647784","immune-reponses-to-rsv-b-challenge-in-older-adults-a-controlled-human-infection-study-with-rsv-in-older-people-02-100647784","NCT07713628","Immune Reponses to RSV B Challenge in Older Adults (A Controlled Human Infection Study With RSV in Older People-02)","CHIRP02 - Immune Reponses to RSV B Challenge in Older Adults (A Controlled Human Infection Study With RSV in Older People-02)","CHIRP02","Inclusion Criteria:\n\n1. Aged between 65 to 75years (inclusive) at Day 0.\n2. Willing and able to commit to participation in the study.\n3. Adequate understanding of the study, the procedures involved, and able to provide written informed consent prior to any study procedures.\n4. In good health with no history of clinically significant medical conditions (as described in exclusion criteria) that would interfere with participant safety. A forced expiratory volume in 1 second (FEV1) and a forced vital capacity (FVC) \\\u003C80% of predicted value calculated using ATS\u002FERS guidance.\n\nExclusion Criteria:\n\n1. Any significant medical condition or prescribed drug deemed by the Investigator to deem the participant unsuitable for the study.\n2. History or evidence of any clinically significant or currently active:\n\n   1. Cardiovascular, thromboembolic or cerebrovascular disease.\n   2. Chronic respiratory disease (e.g. asthma, COPD, rhinitis, sinusitis, reactive airway disease, pulmonary hypertension or a chronic lung condition) in adulthood (a history of childhood asthma without respiratory disease in adulthood may be accepted at the PIs discretion).\n   3. Significant or severe wheeze, or respiratory symptoms (including wheeze) which has ever resulted in hospitalisation.\n   4. Known bronchial hyperactivity to viruses.\n   5. Diabetes mellitus.\n   6. Migraine with associated neurological symptoms such as hemiplegia or vision loss. Cluster headache\u002Fmigraine or prophylactic treatment for migraine.\n   7. History or evidence of autoimmune disease or known\u002Fsuspected immunodeficiency of any cause, including asplenia or history of recurrent severe infections.\n   8. Immunosuppression of any type.\n   9. Known IgA deficiency, immotile cilia syndrome, or Kartagener's syndrome.\n   10. Known coagulation disorder or anticoagulant therapy.\n   11. Psychiatric illness including participants with a history of depression and\u002For anxiety with associated severe psychiatric comorbidities, for example psychosis. Consider exclusion in the following cases: Participants with history of anxiety-related symptoms of any severity within the last 2 years if the Generalized Anxiety Disorder-7 score is ≥4; Participants with a history of depression of any severity within the last 2 years if the Patient Health Questionnaire-9 score is ≥4; . Severe claustrophobia\n   12. Other major disease that, in the opinion of the Investigator, could interfere with a participant completing the study and necessary investigations.\n   13. Concurrent serious illness including history of malignancy that could interfere with the aims of the study or a participant completing the study.\n\n   Permissible stable conditions that are well controlled might not be exclusionary and will be assessed by the PI on a case-by-case basis. These include, but will not be limited to: well controlled Hypertension, Sensitive Bladder, Hiatus Hernia, Vitamin D Deficiency, Diverticulitis, Renal Calculi, Depression (well managed), Perioral Dermatitis, Hypercholesterolemia (diet or well medically controlled), Macular Degeneration, Mild Arthritis.\n3. Any significant abnormality altering the anatomy or function of the nose or nasopharynx in a substantial way, including nasopharyngeal malignancy, arterio-venous malformation, or undiagnosed nasopharyngeal mass.\n4. A history of clinically significant epistaxis (large nosebleeds) within 3 months of Day 0.\n5. Nasal or sinus surgery within 3 months of Day 0.\n6. Any anatomic or neurologic abnormality impairing the gag reflex or associated with increased risk of aspiration.\n7. Receipt of systemic glucocorticoids (in a dose ≥ 5 mg prednisone daily or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within 6 months prior to Day 0.\n8. A history of inhaled bronchodilator or inhaled steroid use within the prior 12 months to Day -14.\n9. Receipt of any vaccine within 30 days of Day -14 or planned during the study period, until the last follow-up visit (Day 90).\n10. Participation in an investigational drug or device study within 3 months prior to Day 0.\n11. Receipt of blood or blood products, or loss (including blood donations) of 550 mL or more of blood during the 6 months prior to Day -14.\n12. History of difficult blood draw, syncope or poor tolerance of sampling procedures as assessed by clinical study team.\n13. History of anaphylaxis and\u002For a history of severe allergic reaction or significant intolerance to any food or drug, as assessed by the PI.\n14. Allergic symptoms present at baseline (at screening, day -14 or day 0).\n15. Clinically active rhinitis (including hay fever) or history of moderate to severe rhinitis, or history of seasonal allergic rhinitis likely to be active at the time of inclusion into the study and\u002For requiring regular nasal corticosteroids on an at least weekly basis, within 30 days of enrolment.\n16. Habitual use of any medication or other product (prescription or over the counter) for symptoms of rhinitis or nasal congestion the 3 months prior to Day -14.\n17. Receipt of RSV vaccine at any time or planned RSV vaccination in the 3 months following inoculation.\n18. Virologically confirmed RSV infection within 6 months of Day 0.\n19. Prior inoculation with a virus from the same virus family (Pneumoviridiae) as the challenge virus.\n20. Prior participation in another controlled human infection study with a respiratory virus in the preceding 6 months taken from the date of viral challenge in the previous study to the date of expected viral challenge in this study.\n21. Acute upper respiratory infection (URI or sinusitis) in the 6 weeks prior to Day-14 baseline visit.\n22. Presence of cold-like symptoms and\u002For fever (defined as participant presenting with a temperature reading of \\>37.9ºC) on Day -14, Day -1 or Day 0.\n23. A respiratory PCR test that is indicative of Influenza, RSV or other respiratory virus infection, including asymptomatic infections, determined by a test on admission to quarantine (Day -1).\n24. Clinically relevant abnormality on chest X-ray.\n25. A total body weight of ≤ 50kg and a Body Mass Index (BMI) ≤18 kg\u002Fm2 or ≥28 kg\u002Fm2.\n\n    • The upper limit of BMI may be increased to ≤ 30kg\u002Fm2 at the PI's discretion, in the case of physically fit muscular individual or other variation of normal).\n26. Any abnormal finding on screening safety blood tests deemed to be clinically significant by the Investigator including positive HIV, active\u002Fchronic hepatitis B or C test.\n27. Any ECG abnormality deemed to be clinically significant by the Investigator.\n28. Significant history or presence of drug or alcohol misuse.\n\n    1. Participants will be required to have a negative urine drug test at screening. If positive, this will be exclusionary.\n    2. Current use of more than 21 units alcohol per week, drug abuse, or regular use of sedatives, hypnotics, tranquilisers or any other addictive agent are exclusionary.\n29. Current use of any recreational drugs, including injected, taken through the nose or inhaled route.\n30. Regular smoking and\u002For vaping and\u002For using other nicotine-containing products in the past 3 months OR:\n\n    1. \\>5 pack-year lifetime history by self-report (5 pack years is equivalent to one pack of 20 cigarettes per day for 5 years).\n    2. Participants will be required to have a negative urine cotinine test at screening. If positive, this will be exclusionary.\n31. Those in close domestic contact (i.e. sharing a household with, caring for, or daily face to face contact) with children under 4 years, clinically vulnerable and\u002For immunosuppressed persons, or those with chronic respiratory disease for 30 days after RSV B inoculation.","65 Years","75 Years",{"count":226,"type":21},20,[24],"This is a human challenge sequential cohort study involving healthy, non-smoking older adults aged 65-75 years. We aim to enrol 20 participants. There will be a sentinel cohort of 6 participants at the beginning of the study (Group 1). If no pausing rules are met, the remaining 14 participants will be enrolled for a total of 20 enrolled participants (Group 2).\n\nThe study will consist of three main phases: (1) screening and baseline, (2) inoculation and quarantine, and (3) follow up.\n\nAll participants will attend a screening visit for a comprehensive health assessment to confirm eligibility.\n\nIf eligible, participants will take part in an inpatient stay in a quarantine unit, where they will be inoculated with 105 plaque-forming units of RSV B-I54 by intranasal drops. The inoculation dose has been determined in the earlier mentioned outpatient study of the same virus strain, in healthy young adults.\n\nDue to the older age range and potentially increased risk of more severe disease, participants will remain within the quarantine unit for 10-days post inoculation and will be closely monitored by clinical review and self-completed symptom diaries. Participants will undergo daily sample collection and will remain in quarantine until the discharge criteria are met at Day 10.\n\nAfter discharge, participants will attend follow-up visits at Day 14, Day 28, and Day 90.\n\nParticipants in Group 2 will have an additional baseline visit at Day -14 where blood, respiratory (nose and throat) and lower airway (bronchoscopy) samples will be collected. Group 2 participants will also undergo a second bronchoscopy during the inpatient period and the third and final bronchoscopy at Day 28.\n\nClinical outcomes will be determined by symptomatology and viral detection in nasal lavage using quantitative PCR. Based on the first-in-human RSV B characterisation study and recent elderly RSV A challenge data, we anticipate approximately 74% attack rate, with a range of mild-moderate symptoms in the infected individuals. Symptoms typically commence 3 days post-inoculation and worsen to peak around days 5-9 before rapidly resolving without treatment. Timing of viral shedding is expected to correlate closely with symptoms.",[230],"RSV","2026-07-14",{"date":159,"type":40},{"date":234,"type":21},"2026-08-01",{"date":236,"type":21},"2028-05-30",{"name":46,"class":47},{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":48},"100611644","volatile-organic-compound-assessment-in-pancreatic-ductal-adenocarcinoma-vapor2-100611644","NCT07243262","Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)","Inclusion Criteria:\n\n* Adult participants ≥ 18 years old\n* Referral from primary care according to the urgent suspected cancer referral guidelines for potential underlying pancreatic cancer, or referral directly to a pancreatic cancer multidisciplinary team meeting\n\nExclusion Criteria:\n\n* Previous pancreatic resection\n* History of another cancer (other than non-melanoma skin cancers) within three years\n* Pregnant participants (pregnancy status to be confirmed verbally with the participant)\n* Participants with co-morbidities preventing breath collection\n* Unable or unwilling to provide informed consent",{"count":245,"type":21},6079,"The investigators are developing a non-invasive breath test to help us detect pancreatic cancer earlier. The test detects small molecules called volatile organic compounds that are made by pancreatic cancers.\n\nPancreatic cancer is a rare disease but patients are often diagnosed at a late stage because their symptoms are the same as those of many common illnesses. This makes it hard for doctors to know which patients need to be tested for pancreatic cancer. If the investigators find pancreatic cancer at a late stage, it reduces the number of treatment choices for patients.\n\nOur test could be offered to patients who are experiencing vague symptoms, which might be caused either by pancreatic cancer or a common illness. This test could help doctors to identify which of those patients may have pancreatic cancer, and ensure they get referred for specialised pancreatic cancer tests. The investigators hope that this will allow us to diagnose pancreatic cancer earlier, increasing treatment choices for patients and improving survival from pancreatic cancer.\n\nThe investigators have previously conducted a study (VAPOR1) which collected breath samples from people with and without pancreatic cancer. When the investigators analysed these samples, they found that there is a difference in the volatile organic compounds breathed out by people who have pancreatic cancer compared to those that do not. The investigators used these 'markers' to develop a breath test to diagnose pancreatic cancer. In VAPOR2, the investigators will study our breath test in a much larger group of patients who have been referred for further investigations for potential underlying pancreatic cancer to see how accurately it can pick up the small percentage of people who have pancreatic cancer.",[154,248],"PDAC - Pancreatic Ductal Adenocarcinoma",[250,251,252,253,254],"Volatile organic compounds (VOCs)","Breath analysis","Volatolomics","Validation","Early detection of cancer","2026-07-07",{"date":257,"type":40},"2026-07-09",{"date":259,"type":40},"2025-10-21",{"date":261,"type":21},"2028-08-01",{"name":46,"class":47},{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":89,"sex":17,"minAge":18,"maxAge":224,"enrollmentInfo":271,"targetDuration":4,"studyType":22,"phases":273,"briefSummary":274,"conditions":275,"keywords":277,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":48},"100645369","phase-2-role-of-a-mitochondrial-receptor-in-blood-sugar-regulation-100645369","NCT07682233","Role of a Mitochondrial Receptor in Blood Sugar Regulation","An Experimental Medicine Study to Investigate the Role of the 18 kiloDalton Translocator Protein in Glucose Metabolism","G-TSPO","Inclusion Criteria:\n\n* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.\n* Aged 18-75 years old\n* A female subject is eligible to participate if she is a) of non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation or hysterectomy, or postmenopausal defined as 12 months of spontaneous amenorrhea or b) of childbearing potential but not pregnant (as determined by urinary pregnancy test on screening and on each study day) and willing to use one of the contraception methods.\n* Male subject must agree to use one of the contraception methods.\n* No history of diabetes.\n\nExclusion Criteria:\n\n* Clinically meaningful abnormalities in routine bloods including:\n\n  * eGFR \\\u003C 60ml\u002Fmin\n  * Elevation of liver enzymes\u002Fbilirubin\n  * Prolonged prothrombin time\n  * Thrombocytopenia\n* Use of the following medications or therapies:\n\n  * P450 CY3A4 inhibitors\n\n    * Potent: Boceprevir, Clarithromycin, Cobicistat, Idelalisib, Itraconazole, Ketoconazole, Nelfinavir, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazoleb\n    * Moderate: Aprepitant, Conivaptan, Crizotinib, Diltiazem, Dronedarone, Erythromycin, Fluconazole, Imatinib, Isavuconazole, Nefazodone, Netupitant, Nilotinib, Posaconazolee, Tofisopam, Verapamil\n    * Unclassified: Delavirdine\n  * P450 CY3A4 inducers\n\n    * Potent: Carbamazepine, Enzalutamide, Fosphenytoin, Mitotane, Phenytoin, Rifampicin\n    * Moderate; Bosentan, Efavirenz, St John's wort\n    * Unclassified; Barbiturates, Nevirapine, Primidone, Rifabutin, Rifapentine\n  * oral contraceptives\n  * oral anticoagulants or antiplatelet agents other than low dose aspirin\n  * levothyroxine\n* Currently breastfeeding.\n* Any clinical significant medical conditions that in the opinion of the investigator would compromise subjects' safety or compliance with study procedures.\n* History of any clinical condition which in the opinion of the principal investigator would compromise the scientific integrity of the study, such as some chronic systemic diseases affecting blood, liver or kidneys or endocrine system.\n* Unwillingness or inability to follow the procedures outlined in the protocol.\n* Subject is mentally or legally incapacitated.\n* Contraindication to XBD173 use:\n\n  * Hypersensitivity to the active substance or to any of the excipients",{"count":272,"type":21},50,[118],"The goal of this clinical trial is to learn whether a single dose of XBD173, a medicine that binds to a protein called the 18 kiloDalton Translocator Protein (TSPO), affects how the body processes glucose in healthy volunteers aged 18 to 75 years.\n\nThe main questions it aims to answer are:\n\n* Does a single dose of XBD173 change fasting blood glucose levels compared with placebo?\n* Does a single dose of XBD173 change blood glucose levels after participants drink a glucose solution compared with placebo?\n\nResearchers will compare XBD173 with a placebo, which does not contain the active medicine, to see whether activating TSPO affects glucose metabolism in the fasting state and after a glucose drink.\n\nParticipants will:\n\n* Attend a screening visit to confirm eligibility, including a medical history, physical examination and blood tests.\n* Attend four study visits after fasting overnight: two visits involving a glucose drink and two visits without a glucose drink.\n* Receive a single oral dose of XBD173 at some visits and placebo at other visits. The order will be randomised, and neither participants nor the study team conducting the assessments will know which treatment is given during each visit.\n* Have repeated blood samples taken through a cannula to measure glucose, insulin and other markers related to metabolism and inflammation.\n* Have resting energy use measured by breathing under a transparent canopy connected to a standard metabolic measurement device.\n* Have blood pressure, heart rate, height and weight measured.\n* Undergo measurement of blood vessel function using a cuff.",[276],"Heathly Volunteers",[278,279,280,281,282,283,284,285,286,287,288,289,290,291],"TSPO","18 kDa Translocator Protein","XBD173","Glucose Metabolism","Fasting Plasma Glucose","Oral Glucose Tolerance Test","OGTT","Insulin Response","Resting Energy Expenditure","Respiratory Quotient","Healthy Volunteers","Randomised Controlled Trials","Randomised Crossover Study","Placebo-Controlled Trial","2026-06-26",{"date":294,"type":40},"2026-07-02",{"date":296,"type":40},"2026-03-27",{"date":298,"type":21},"2028-09-01",{"name":46,"class":47},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":307,"targetDuration":309,"studyType":59,"phases":4,"briefSummary":310,"conditions":311,"keywords":316,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":272},"100642865","the-uk-22-week-study-100642865","NCT07616778","The UK 22 Week Study","Clinical Management and Short-Term Outcomes of Neonates Born at 22 Weeks in the UK (The 22 Week Study)","Inclusion Criteria:\n\n* Born at 22+0-22+6 weeks gestational age\n* Born in a NICU centre with neonatal team in attendance\n* Or admitted to a NICU within first 72 hours of life if outborn\n\nExclusion Criteria:\n\n* Less than or more than 22 weeks gestation at birth\n* Known congenital anomaly",{"count":308,"type":21},100,"6 Months","In the UK, babies born at 22 weeks of pregnancy have only been offered survival-focused care (sometimes called resuscitation or stabilisation) since 2019. Very few babies are born this early each year and sadly a lot of them do not survive. Therefore, healthcare teams don't have much information about this new population of tiny babies and there is much to learn about how they respond, the problems they face and the best way for intensive care units to look after them.\n\nThis study aims to collect information available in babies' medical notes, analyse it and share learning to start improving this knowledge. There will be no changes to the babies' care, only observation of what happens.\n\nA small team of doctors and nurse practitioners who have\u002Fare looking after a baby, will put a small amount of selected information, without 'identifiers' such as the baby's name, date of birth or hospital number, onto a secure database platform at Imperial College London (a university).\n\nResearchers will analyse the information from all the babies around the UK together to look for trends and to describe common things that happen to them, as well as their outcomes.\n\nParents will be made aware this information is being collected and used through a leaflet. It will not be possible to identify an individual baby in the results.\n\nThe investigators are aiming for around 45 hospitals across the UK to participate. Babies born at 22 weeks gestation, who are attended to at birth by a neonatal team (or admitted) at an intensive care site over a 12-month period will be included. While collecting this information will not impact the babies included, it may help the treatment of babies born early in the future and give families more accurate information about what they might expect to happen.",[312,313,314,315],"Extreme Prematurity - Less Than 28 Weeks","Infant, Extremely Premature","Neonatal and Perinatal Conditions","Intensive Care, Neonatal",[317,318,319],"Neonatal","extreme prematurity","observational","2026-06-23",{"date":322,"type":40},"2026-06-24",{"date":324,"type":40},"2025-06-01",{"date":326,"type":21},"2027-12",{"name":46,"class":47},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":22,"phases":336,"briefSummary":337,"conditions":338,"keywords":342,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":354},"100622653","study-of-lesion-specific-invasive-haemodynamic-angina-thresholds-100622653","NCT07386418","Study of Lesion-Specific Invasive Haemodynamic Angina Thresholds","ORBITA-SOLAR","Inclusion Criteria:\n\n1. Eligibility for PCI due to angina or angina-equivalent symptoms on exertion\n2. 2 severe epicardial stenoses in a major coronary artery, defined as:\n\n   1. ≥70% stenosis in a coronary artery with ≥2.5mm diameter, on invasive coronary angiography (ICA)\n   2. Severe stenosis in a vessel with ≥2.5mm diameter, on CTCA\n3. Evidence of ischaemia on an invasive or non-invasive test, including:\n\n   1. Physiological test during invasive coronary angiography (ICA)\n   2. Dobutamine stress echocardiography (DSE)\n   3. Stress perfusion cardiac magnetic resonance (CMR)\n   4. Myocardial perfusion scintigraphy (MPS)\n   5. Fractional flow reserve computed-tomography (FFR-CT)\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years\n2. Acute coronary syndrome within 3 months\n3. Previous coronary artery bypass graft\n4. Significant left main stem disease\n5. Single lesion amenable to PCI\n6. Chronic total occlusion of the target artery\n7. Moderate to severe valve disease\n8. LVEF ≤40%, contraindication to PCI or drug-eluting stents\n9. PCI performed with drug-eluting balloons without stenting\n10. Contraindication to antiplatelet therapy\n11. Contraindication to adenosine\n12. Physical inability to exercise with an ergometer\n13. Femoral artery access\n14. Pregnancy\n15. Inability to consent",{"count":91,"type":21},[24],"ORBITA-SOLAR is an invasive physiological cardiac catheterisation study that aims to determine whether different coronary stenoses have different angina thresholds. The angina threshold is defined as the amount of coronary flow reduction required to reproduce symptoms. Sixty patients with symptoms of stable angina and 2 coronary artery stenoses amenable to percutaneous coronary intervention (PCI) will be recruited. This study will use intra-coronary balloon inflation during supine exercise on an ergometer to measure the fractional flow reserve (FFR) and non-hyperemic pressure ratio (NHPR) that relates to angina onset, in real time, at the location of each stenosis.",[339,340,341],"Angina (Stable)","Coronary Artery Disease(CAD)","Ischaemic Heart Disease (IHD)",[343,344,345,346,347],"Angina","Coronary physiology","Coronary haemodynamics","Placebo-control","Symptoms",{"date":292,"type":40},{"date":350,"type":40},"2026-02-10",{"date":352,"type":21},"2028-12",{"name":46,"class":47},7,{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":22,"phases":364,"briefSummary":365,"conditions":366,"keywords":369,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":381},"100520123","physiological-versus-right-ventricular-outcome-trial-evaluated-for-bradycardia-treatment-upgrades-100520123","NCT06052475","Physiological Versus Right Ventricular Outcome Trial Evaluated for Bradycardia Treatment Upgrades","PROTECT-UP","Patients with an RV pacemaker and LVEF 35-50% and a high burden of right ventricular pacing (\\>40%) who are clinically indicated for a cardiac resynchronisation therapy upgrade procedure and:\n\n1. EF reduced by \\>5% of increase in LVESV by 10ml since implant\n2. NT-proBNP \\>250ng\u002FL in sinus rhythm\n3. NT-proBNP \\> 750 Ng\u002FL if AF\n4. Left atrial volume index \\> 30ml\u002Fm2\n5. Regular loop diuretics prescribed\n6. Decline in daily patient activity by \\>1 hour per day since implant\n7. Decrease in device measured thoracic impedance\n8. Patient reported decline in functional class or exercise tolerance\n\nExclusion Criteria:\n\n* Those unable to provide informed consent\n* Patients under age 18\n* Pregnant women",{"count":363,"type":21},155,[24],"Guidelines for patients having first-time implants advocate that even when heart function is only mildly impaired, modern pacing approaches should be utilised to avoid the potentially damaging effects of RV pacing to preventing symptoms from pacing induced or worsened cardiomyopathy.\n\nHowever, once a traditional (RV) pacemaker is implanted, development of impaired heart function does not prompt a device upgrade. Even at the end of battery life, physicians simply replace it like-for-like.\n\nThis trial tests whether such patients have better symptoms and quality of life if changed to a modern physiological pacing strategy from the traditional RV pacing approach.\n\nIn this crossover trial, participants will be upgraded to a physiological pacing strategy.\n\nAfter their procedure, they will have a one-month run-in period to recover from the procedure (their pacemaker will be programmed to continued RV pacing).\n\nThey will be have 2 one-month blinded time periods, randomised to physiological pacing or right ventricular pacing alternately. They will subsequently undergo two six-month blinded randomised time periods.\n\nPatients will document symptoms monthly on a mobile phone application or computer. At the end of each time period, they will have measurements of heart function, a walking test and quality-of-life questionnaires including the SF-36 questionnaire.\n\nThe investigators hypothesise that upgrading to physiological pacing strategies will improve patients' quality of life.",[367,368],"Pacing-Induced Cardiomyopathy","Heart Failure",[370,371,372,373],"Physiological Pacing","RV Pacing","Biventricular Pacing","Pacemaker Upgrade","2026-06-22",{"date":320,"type":40},{"date":377,"type":40},"2023-09-04",{"date":379,"type":21},"2027-09-04",{"name":46,"class":47},12,{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":224,"enrollmentInfo":389,"targetDuration":4,"studyType":22,"phases":391,"briefSummary":392,"conditions":393,"keywords":398,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":48},"100643847","3d-reconstruction-vr-and-machine-learning-in-body-image-in-bariatrics-100643847","NCT07668492","3D Reconstruction, VR and Machine Learning in Body Image in Bariatrics","The Use of 3D Reconstruction, Virtual Reality, and Machine Learning in Addressing Body Image in Bariatric Metabolic Surgery.","Inclusion Criteria:\n\n* Tier 4 bariatric group\n* On waiting list for bariatric metabolic surgery\n* Able to stand unaided for at least 5 minutes\n\nExclusion Criteria:\n\n* Anyone who cannot provide informed consent\n* Anyone who is involved in current research or has recently been involved in any research prior to recruitment.",{"count":390,"type":21},80,[24],"Studies have shown that following bariatric metabolic surgery (BMS), patients continue to experience dissatisfaction with their new body image and identity). The reason for this is poorly understood but negative body image perception after surgery is linked to poor psychological and clinical outcomes. Our pilot study looking at the acceptability and feasibility of 3D reconstruction and virtual reality (VR) in addressing body image in BMS found that participants felt better informed about how their body will change following significant weight loss and agreed this novel intervention would be beneficial in helping patients adjust to changes in their body after BMS.\n\nThe investigators propose a randomised control trial comparing group body image counselling and group body image counselling with 3D reconstruction and VR in addressing body image in BMS. The study aims to enrol 80 participants from the Tier 4 bariatric group at St Mary's Hospital and Chelsea \\& Westminster Hospital. After consent, participants will be divided into two groups: the control group will receive traditional group body image counselling, and the intervention group will receive the same counselling supplemented with VR and 3D reconstructed images depicting 15% and 25% total less body weight. Both groups will undergo four sessions over six months.\n\nThe investigators will collect data including body measurements and 3D images of the participant in their underwear using a secure password protected device at baseline and follow participants at 3, 6, 9, 12, 18, 24, and 36 months post-BMS. Patient reported outcomes will be assessed through patient-reported questionnaires.\n\nThis trial seeks to determine if integrating 3D reconstruction and VR technology into body image counselling can provide better support for patients adjusting to body image changes post-BMS, potentially leading to improved psychological and clinical outcomes.",[394,395,396,397],"Obesity (Disorder)","Body Image","Mental Health","Bariatric Surgery",[399,400,395,401,402],"3D Reconstruction","Virtual Reality","Machine Learning","Bariatric Metabolic Surgery","2026-06-19",{"date":405,"type":40},"2026-06-25",{"date":407,"type":21},"2026-06",{"date":409,"type":21},"2030-03",{"name":46,"class":47},{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":421,"conditions":422,"keywords":424,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":4},"100641375","an-observational-study-into-antimicrobial-resistance-in-patients-with-a-chronic-lung-disease-100641375","NCT07646691","An Observational Study Into Antimicrobial Resistance in Patients With a Chronic Lung Disease","Prospective Study of Antimicrobial RESIstance in Chronic Lung DiseasE","PRESIDE","Inclusion Criteria:\n\n* Presence of an underlying chronic lung disease (e.g. Bronchiectasis, COPD) stratified by colonisation status:\n\n  * Pseudomonas sp (n=30)\n  * Klebsiella sp (n=20)\n  * Haemophilus sp (n=20)\n  * E-coli sp (n=20)\n  * Stenotrophomonas sp (n=20)\n  * Staphylococcus sp (n=20)\n  * Other chronic colonisation (n=20)\n  * Not colonised with any bacterial pathogen (n=20)\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Pregnancy\n* Medical instability preventing ability to attend for regular study visits at baseline.",{"count":420,"type":21},170,"Antimicrobial resistance (AMR) refers to the ability of microorganisms like bacteria, viruses, fungi and parasites to resist the effects of antimicrobial drugs (such as antibiotics) which are widely used as treatment. AMR poses an escalating global health threat, contributing to difficult-to-treat infections associated with increased disease spread, disability and death, as well as a substantial economic burden.\n\nIn chronic lung diseases, such as bronchiectasis, Cystic fibrosis or chronic obstructive lung disease (COPD), there is a higher risk of AMR due to the exposure to frequent or prolonged courses of antibiotics to treat recurrent lung infections and exacerbations (flares of the disease), to reduce lung inflammation or to control chronic infection within the lung with suppression of colonising microbes.\n\nMost data on AMR in chronic lung diseases derive from analysing pre-existing routinely collected health data collected on a national basis which is often incomplete. Hence a prospective study is crucial to better understand and address AMR in chronic lung diseases. Prospective studies follow patients forward in time, collecting data on outcomes and allowing researcher to observe the natural history of AMR development, monitor trends and evaluate interventions.\n\nThis multicentre prospective study, as part of the European Respiratory Society (ERS) Clinical Research Collaboration on Antimicrobial Resistance in Lung Disease (CRC - AMR Lung), aims to investigate the patterns of AMR in chronic lung diseases through a fully anonymous registry alongside a prospective sub-cohort study tracking individuals with chronic lung disease and known colonisation with high-priority AMR pathogens (microorganisms). This study will enable analysis of prevalence and burden of AMR within chronic lung disease alongside understand the genetic drivers of resistance, the link between the microbial genotype and antimicrobial resistance and how transmission of resistance occurs in chronic lung disease.",[423],"Chronic Lung Diseases",[425,426],"antimicrobial resistance","chronic lung disease","2026-06-17",{"date":374,"type":40},{"date":430,"type":21},"2026-07-01",{"date":432,"type":21},"2028-12-01",{"name":46,"class":47},{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":440,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":22,"phases":444,"briefSummary":445,"conditions":446,"keywords":449,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":461,"leadSponsor":463,"locationsCount":464},"100644401","tackling-resistance-and-healthcare-economics-through-cpe-screening-100644401","NCT07663110","Tackling Resistance And HealthCare Economics Through CPE Screening","Multi-centre Evaluation of Carbapenemase-producing Enterobacterales (CPE) Prevalence and Transmission Dynamics, Recommendations on Screening Strategies, and Health Economics Outcomes Research Impact to Inform Policy Change","TRACE-CPE","Inclusion Criteria:\n\n* All adult (18 years or older) medical patients admitted to the acute medical unit during the implementation period who undergo routine rectal CPE testing as per local Trust policy and test positive for CPE colonisation through either the rapid test or culture-based methods.\n\nExclusion Criteria:\n\n* Patient refusal for rectal screening or\n* Clinical contraindication to rectal swab collection",{"count":443,"type":21},16000,[24],"The goal of this clinical study is to learn if it is possible to reduce the spread of resistant bacteria called CPEs (Carbapenemase producing Enterobacterales) between patients admitted to hospital.\n\nCPEs can be carried in the gut of people without making them ill. Normally when patients come into hospital, they may undergo a swab test on their bottom to see if CPEs can be grown. This test can take up to 24 hours to produce a result.\n\nThe investigators want to use a faster test which takes 2 hours to produce a result, and whether this can make a difference to CPE spread between person to person.\n\nThe main questions it aims to answer are:\n\n1. Why do people carry, transmit or get infected with CPE?\n2. If a faster test was used to look for CPE, would this be better at reducing patient spread in hospital?\n3. Is a faster test also more cost effective?\n\nParticipants will:\n\n1. Be tested by both the usual and faster test when they come into hospital by a swab on their bottom\n2. Where they test positive for CPE they will be asked to answer some questions about their health",[447,448],"Carbapenem-Resistant Enterobacteriaceae","Colonisation",[450,451,452,453,454,455,456,457],"infection prevention and control","health economics","rapid molecular diagnostics","carbapenem-resistant Enterobacterales","CPEs","CROs","MDROs","hospital transmission","2026-06-16",{"date":320,"type":40},{"date":234,"type":21},{"date":462,"type":21},"2028-03-31",{"name":46,"class":47},2,{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":22,"phases":475,"briefSummary":477,"conditions":478,"keywords":4,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":48},"100495779","phase-4-thromboprophylaxis-in-individuals-undergoing-superficial-endovenous-treatment-thrive-100495779","NCT05735639","THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) - a Multi-centre Assessor-blind Randomised-controlled Trial","THRIVE","Inclusion Criteria:\n\n* Adults (\\>18 years)\n* Scheduled to undergo endovenous intervention of truncal varicose veins under local anaesthesia\n* Treatment technologies including radiofrequency, laser, mechanochemical, foam sclerotherapy and cyanoacrylate glue\n\nExclusion Criteria:\n\n* Clinical indication for therapeutic anticoagulation e.g., atrial fibrillation\n* Previous personal or first-degree relative history of VTE\n* Thrombophilia\n* Female patients of childbearing potential who have a positive pregnancy test\n* A history of allergy to heparins or direct oral anticoagulants\n* A history of heparin-induced thrombocytopenia\n* Inherited and acquired bleeding disorders\n* Evidence of active bleeding\n* Concomitant major health problems such as active cancer and chronic renal and\u002For liver impairment\n* Known thrombocytopenia (platelets known to be less than 50 x 109\n\n  \u002Fl)\n* Surgery or major trauma in the previous 90 days\n* Recent ischemic stroke in the previous 90 days\n* Inability to provide consent",{"count":474,"type":21},3175,[476],"PHASE4","Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself. Varicose veins are enlarged veins close to the surface of the skin. They are connected to the bigger deeper veins in the leg (known as deep veins). Because of this, operations to close the varicose veins can increase the chance of a blood clot forming in the deep veins. Blood clots in the deep veins happen in around 1 in 50 people after endovenous operations. A clot in the leg can cause swelling, pain, and other long-term problems. If a clot in the leg breaks off and travels to the lungs, it can cause problems with the lung' ability to move oxygen from the air into the blood and may, in rare cases, be life threatening.\n\nVaricose vein procedures may carry a slightly higher risk of blood clot formation, and we are currently unsure if current clot reducing medicines are beneficial in preventing blood clots in people having varicose vein procedures.\n\nThis study will investigate if it is worthwhile prescribing medicines to reduce blood clots after varicose vein procedures.",[479,480],"Venous Thromboembolism","Varicose Veins","2026-06-03",{"date":483,"type":40},"2026-06-04",{"date":485,"type":40},"2024-01-22",{"date":487,"type":21},"2027-12-31",{"name":46,"class":47},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":89,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":22,"phases":498,"briefSummary":499,"conditions":500,"keywords":504,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":511,"leadSponsor":513,"locationsCount":514},"100639991","long-axial-field-of-view-lafov-18ffdg-petct-imaging-in-large-vessel-vasculitis-lvv-protocol-optimisation-study-100639991","NCT07628075","Long-Axial Field of View (LAFOV) [18F]FDG PET\u002FCT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.","LAVA-FLOW","Inclusion Criteria LVV Patients:\n\n* ≥18 years of age\n* Newly diagnosed LVV (based on the 2022 American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) classification criteria or from a definite diagnosis of LVV on standard of care imaging)\n* WHO performance status 0-2\n* The subject is able and willing to comply with study procedures and signed and dated informed consent is obtained\n* eGFR of ≥30 (mL\u002Fmin\u002F1.73m2) within 3 months of \\[18F\\]FDG injection in subjects who have a history of renal impairment, renal disease, renal transplant or diabetes\n\nExclusion Criteria LVV Patients:\n\n* The subject is pregnant or lactating\n* Participants with claustrophobia or who are unable to comfortably tolerate the scanning procedure\n* History of allergy to iodinated contrast\n* Commencement of steroids \\> 7 days prior to administration of the radiotracer\n* Poorly controlled diabetic with a blood glucose \\>11mmol\u002FL\n* Evidence of a significant medical condition or laboratory finding which, in the opinion of the Investigator, makes it undesirable for the patient to participate in the trial.\n\nInclusion Criteria Healthy Volunteers:\n\n* Three subjects ≥18 years of age that are also \\\u003C 50 years old and three subjects ≥50 years of age\n* WHO performance status 0-2\n* The subject is able and willing to comply with study procedures and signed and dated informed consent is obtained\n\nExclusion Criteria Healthy Volunteers:\n\n* The subject is pregnant or lactating\n* Participants with claustrophobia or who are unable to comfortably tolerate the scanning procedure\n* Participants with any contra-indication to MRI\n* Known allergy to gadolinium-based contrast agents\n* History of smoking\n* History or current diagnosis of the following medical conditions:\n* Diabetes Mellitus\n* Chronic Kidney Disease\n* Atrial Fibrillation\n* Migraines\n* Rheumatoid Arthritis\n* Systemic Lupus Erythematosus (SLE)\n* Historic or current prescription of the following medications:\n* Any blood pressure medication\n* Any antipsychotic medication\n* Steroids\n* Weight of ≥75Kg (in order to keep the radiation dose \\\u003C10mSV for HV)\n* Evidence of any significant medical condition which, in the opinion of the Investigator, makes it undesirable for the HV to participate in the trial\n* Participants that have undergone any imaging investigation that exposes them to radiation within the previous 12 months",{"count":497,"type":21},18,[24],"Large vessel vasculitis (LVV) is an autoimmune inflammatory disorder affecting the major arteries of the body. The diagnosis and monitoring this condition can be challenging, as patients often present with symptoms that are unclear, and the diagnostic criteria currently used are varied. Accurate diagnosis is essential because it helps to tailor the treatment to each patient. Some treatments, such as steroids and immunosuppressive medications, can have significant side effects, so they need to be used carefully and only when truly needed.\n\nAn \\[18F\\]FDG Positron Emission Tomography\u002FComputed Tomography (PET\u002FCT) involves the injection of a small amount of radiolabelled sugar, which assesses glucose metabolism within the body. \\[18F\\]FDG PET\u002FCT is already used by the NHS to detect inflammation within the vessel walls and diagnose LVV. Current diagnostic criteria for LVV largely rely on visual assessment by a radiologist. This approach therefore has limitations and may not fully capture changes in the levels of inflammation over time.\n\nA new generation of scanners, known as Long Axial Field-of-View (LAFOV)-PET\u002FCT or Total Body PET, are currently transforming what is possible in the field of medical imaging. These LAFOV-PET\u002FCT scanners have new digital detectors that are more sensitive, produce sharper images, and can scan the entire body rapidly. This offers several potential advantages for patients with LVV, including the clearer detection of vessel wall inflammation, the ability to administer lower doses of the radiolabelled sugar (\\[18F\\]FDG), and the ability to take repeated pictures over time to measure subtle changes in blood flow and inflammation. Patients receiving a routine NHS \\[18F\\]FDG PET\u002FCT scan for LVV are typically scanned 60 minutes after injection of the radiotracer using a standard PET\u002FCT. Another benefit of LAFOV-PET\u002FCT scanners is their ability to assess the amount of the radiolabelled sugar taken up by the whole body almost as soon as it is injected which could give important additional information.\n\nAs part of the LAVA-FLOW study we are planning to combine LAFOV-PET\u002FCT with a CT Angiogram (CTA) in patients with LVV. A CTA is a scan that shows doctors what your blood vessels look like. It involves the injection of a dye into a vein that makes your blood vessels visible, highlighting vessel wall inflammation and vessel wall narrowing. This combination of LAFOV-PET\u002FCT and CTA therefore has the potential to give a much more detailed picture of LVV than is achievable using current methods.\n\nThe LAVA-FLOW study therefore aims to develop a standardised protocol to be used in different hospital centres across the UK for the imaging of LVV using LAFOV-PET\u002FCT. We also hope that the results of this particular study could lead to further larger studies with the potential to update the diagnostic criteria and improve the monitoring of this condition.",[501,502,503],"Large Vessel Vasculitis","Takayasu Arteritis","Giant Cell Arteritis (GCA)",[501,505,506,507],"[18F]FDG Long-Axial Field of View (LAFOV)-PET\u002FCT","Angiography","Protocol Optimisation","2026-06-01",{"date":483,"type":40},{"date":430,"type":21},{"date":512,"type":21},"2028-01-01",{"name":46,"class":47},3,{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":521,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":523,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":525,"conditions":526,"keywords":528,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":4},"100639601","womens-knowledge-about-induction-of-labour-and-its-association-with-their-experience-100639601","NCT07616765","Women's Knowledge About Induction of Labour and Its Association With Their Experience","Induction of Labour: Women's Knowledge and Experience","INFORM","Inclusion Criteria:\n\nWomen:\n\n* All pregnant women who are booked for IOL at Chelsea and Westminster Hospital NHS Foundation Trust which includes both Chelsea and Westminster Hospital and West Middlesex Hospital.\n* The ability to understand and sign a written informed consent form.\n* Singleton pregnancy.\n\nClinicians:\n\n• Working at Chelsea and Westminster Hospital NHS Foundation Trust which includes both Chelsea and Westminster Hospital and West Middlesex Hospital.\n\nExclusion Criteria:\n\nWomen:\n\n* Under age 18\n* Women who do not have sufficient understanding of the English language to provide informed consent or to complete the questionnaires and interviews independently\n* Those not meeting the inclusion criteria\n\nClinicians:\n\n• Those not meeting the inclusion criteria",{"count":524,"type":21},112,"Induction of labour (IOL) is a common procedure to initiate childbirth, around one in three pregnant women having their labour induced in the UK. Labour may be induced for many different reasons, including going past the due date, having high blood pressure, diabetes, concerns about the baby's growth, or reduced movements.\n\nIOL can be a complex and lengthy process, sometimes lasting up to seven days. Many women find that their expectations of IOL do not match their real experiences. Research shows that between 5% and 20% of women report a negative birth experience, and this can have lasting effects. These may include difficulties bonding with their baby, depression after birth, fear of future childbirth, or choosing a caesarean section next time.\n\nStudies also show that women who feel unprepared for induction, or who do not fully understand the benefits, risks, and steps involved, are more likely to have a difficult experience. At the same time, research suggests that some healthcare professionals may not feel fully confident in their knowledge of induction, and their decisions may be influenced by colleagues or local practice rather than evidence alone.\n\nThis project aims to understand how much women know about induction before it begins, how this knowledge affects their experience, and how well clinicians understand and communicate about induction.\n\nTo do this, investigators will invite women who are booked for induction at Chelsea and Westminster Hospital or West Middlesex Hospital to take part in two surveys: one before induction and one after birth. Women will also be able to volunteer for an interview to talk in more detail about their experience. They will also invite all maternity staff at the Trust to complete a short survey about their knowledge and attitudes towards induction, followed by optional interviews.\n\nInvestigators aim to recruit approximately 82 pregnant women and 20 to 30 clinicians (including midwives, obstetricians, and trainees) working in the maternity department at Chelsea and Westminster Hospital NHS Foundation Trust.",[527],"Induction of Labour",[529,530,531,532,533,534,535,536],"Induction of labour","Patient satisfaction","Pregnancy","Clinicians","Attitude","Maternity care","Women's Knowledge","Labour Induction","2026-05-27",{"date":508,"type":40},{"date":540,"type":21},"2026-05-01",{"date":542,"type":21},"2028-05-01",{"name":46,"class":47},{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":89,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":554,"conditions":555,"keywords":556,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":48},"100495118","volatile-organic-compound-assessment-in-pancreatic-ductal-adenocarcinoma-100495118","NCT05727020","Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma","Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR 1 \u002F BIORESOURCE)","VAPOR","Inclusion Criteria:\n\n* Males and females\n* Adult patients ≥ 18 years old\n* VAPOR 1: patients with either a) Histologically confirmed PDAC\\*; b) New-onset diabetes mellitus or chronic pancreatitis; or c) Non-specific gastrointestinal symptoms, but a radiologically-normal pancreas\n* VAPOR Bioresource: patients undergoing pancreatic resection for a) Histologically confirmed PDAC\\*; or b) Benign pancreatic disorders e.g. intraductal papillary mucinous neoplasms, pancreatic mucinous cystic neoplasms, chronic pancreatitis\n\nNote: \\*Patients undergoing surgery for suspected PDAC (without pre-operative histological confirmation) may be recruited assuming PDAC is confirmed within the resected specimen.\n\nExclusion Criteria:\n\n* Patients who have already received chemotherapy, radiotherapy or surgery for their PDAC\n* History of another cancer within the previous five years\n* Previous upper gastrointestinal surgery\n* Patients who are unable to provide a breath sample\n* Pregnant women\n* Patients unable to provide informed written consent\n* VAPOR 1: Patients with active infection, receiving immunosuppressive medications or antibiotics within the preceding eight weeks\n* VAPOR Bioresource: Patients receiving immunosuppressive medications within the preceding eight weeks",{"count":553,"type":21},1005,"Patients with early pancreatic cancer often have symptoms that could also be caused by many common benign conditions, or no symptoms at all. Jaundice, weight loss and pain are 'red flag' symptoms of pancreatic cancer that are linked to incurable disease. At the moment only patients with 'red flag' symptoms are urgently referred for diagnostic testing to find out if they have the cancer. As a result, late diagnosis is a common feature of pancreatic cancer. This leads to limited treatment options being available to patients by the time they are diagnosed, and ultimately results in poor survival rates.\n\nThere is a clear need to improve earlier detection of pancreatic cancer so that patients with pancreatic cancer can be identified earlier and faster, enabling them to start treatment more quickly.\n\nThe study team is developing a non-invasive breath test that detects small molecules called volatile organic compounds (VOCs) that may be altered by pancreatic cancers. For patients with non-specific symptoms, this test would help general practitioners (GPs) to identify those patients that may indeed have an underlying pancreatic cancer, who would benefit from referral for specialised pancreatic cancer tests.",[248,154],[250,251,252,557,558,559,560,561],"Metabonomics \u002F Lipidomics","Transcriptomics","Microbiome Analysis","Organoids","Immune profiling","2026-05-15",{"date":564,"type":40},"2026-05-18",{"date":566,"type":40},"2022-12-15",{"date":568,"type":21},"2028-08",{"name":46,"class":47},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":89,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":22,"phases":579,"briefSummary":580,"conditions":581,"keywords":4,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":587,"leadSponsor":589,"locationsCount":48},"100520842","artificial-intelligence-delivered-cardiac-magnetic-resonance---prospective-validation-100520842","NCT06061822","Artificial Intelligence Delivered Cardiac Magnetic Resonance - Prospective Validation","AID-MR","Inclusion Criteria:\n\n* Adult (aged at least 18 years)\n\nExclusion Criteria:\n\n* Children (patients below age 18).\n* Pregnant patients.",{"count":578,"type":21},150,[24],"Cardiac MRI (CMR) scanning allows doctors to create detailed images of the heart. However, the need for experienced cardiac radiographers to perform each scan can make CMR's delivery difficult, and some patients in the UK wait more than half a year for a scan. These radiographers must take pictures of different part of the heart, termed \"views\", each of which must be precisely positioned.\n\nThe investigators believe they can revolutionise CMR, by using artificial intelligence to automatically position the views so radiographers can focus on more difficult tasks.\n\nThe investigators have used a retrospective database of pseudonymised (anonymised and linked) CMR scans at our hospital to create these artificial intelligence (AI) algorithms, and they have validated them retrospectively on previous studies. The investigators now wish to test the algorithms prospectively.\n\nIn this study, the investigators will recruit patients undergoing clinical CMR scans. In addition to the routine images acquired by expert radiographers, the investigators will require a duplicate set of images, positioned and planned by the AI algorithms.\n\nThe investigators will then compare, within each patient, the AI-planned and expert-radiographer-planned scanning in terms of both speed and image quality.",[582,288],"Cardiovascular Diseases","2026-05-06",{"date":585,"type":40},"2026-05-11",{"date":540,"type":40},{"date":588,"type":21},"2027-12-01",{"name":46,"class":47},{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":22,"phases":597,"briefSummary":598,"conditions":599,"keywords":602,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":48},"100635677","motivating-core-muscle-exercises-with-wearable-sensors-haptics-and-interactive-gaming-100635677","NCT07555795","Motivating Core-muscle Exercises With Wearable Sensors, Haptics and Interactive Gaming","Inclusion Criteria:\n\n1. Over the age of 18\n2. Non-specific LBP for at least 6 weeks in the past 12 months\n3. Pain 4\u002F10 on a visual analogue scale or more or Oswestry Disability Index over 20%\n\nExclusion Criteria:\n\n1. Serious spinal pathology (\"red flags\") such as:\n\n   * History of malignancy with new onset back pain suggestive of recurrence.\n   * Unexplained weight loss, fever, or systemic symptoms.\n   * Recent significant trauma (e.g., fall from height, road traffic accident).\n   * Suspected or confirmed spinal infection (e.g., discitis, osteomyelitis).\n   * Cauda equina symptoms, including urinary retention\u002Fincontinence or saddle anaesthesia.\n   * Progressive neurological deficit (e.g., worsening weakness, loss of reflexes).\n2. Recent spinal surgery or invasive spinal procedures within the past 3 months.\n3. Severe cardiovascular or respiratory disease that prevents safe participation in mild to moderate exercise (e.g., unstable angina, uncontrolled heart failure).\n4. Pregnant women or those less than three months postpartum.\n5. Known allergy to materials used in the belt (e.g., Lycra or related fabrics).\n6. Cognitive impairment that prevents informed consent or ability to follow exercise instructions.\n7. Concurrent participation in another intervention trial that may interfere with the study outcomes.",{"count":58,"type":21},[24],"The goal of this clinical trial is to evaluate whether a wearable biofeedback smartbelt system can improve pain and disability in adults with chronic lower back pain. The intervention combines a wearable belt that measures muscle activity with a mobile application that provides real-time feedback during exercise.\n\nThe main questions it aims to answer are:\n\n* Does the MMG-biofeedback system improve disability, as measured by the Oswestry Disability Index (ODI), compared to standard care alone over an 8-week period?\n* Does the system reduce perceived pain levels and improve exercise adherence in individuals with lower back pain over an 8-week period?\n\nResearchers will compare participants receiving the MMG-biofeedback belt alongside standard care to those receiving standard care alone to determine whether the addition of real-time muscle activation feedback leads to improved outcomes.\n\nParticipants will:\n\n* Be randomly assigned to either the intervention group (biofeedback system + standard care) or control group (standard care only)\n* Complete an 8-week home-based exercise programme, all participants are asked to complete the programme at least 5 times a week\n* Use the wearable belt and mobile application during exercise sessions (intervention group only)\n* Receive a booklet with the exercise programme and video links (control group only)\n* Complete questionnaires on pain, disability, and usability at baseline and after 8 weeks, and at a 3-month follow-up\n* Have their exercise adherence and engagement monitored throughout the study\n\nThe study includes an initial pilot phase to assess feasibility, followed by a larger randomised controlled phase to evaluate early clinical effectiveness.",[600,601],"Non-specific Low Back Pain","Low Back Pain",[603,604,605,606],"wearables","core muscle","exercise therapy","biofeedback","2026-04-21",{"date":609,"type":40},"2026-04-29",{"date":611,"type":40},"2026-04-20",{"date":613,"type":21},"2027-04-20",{"name":46,"class":47},{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":89,"sex":17,"minAge":18,"maxAge":623,"enrollmentInfo":624,"targetDuration":4,"studyType":22,"phases":626,"briefSummary":627,"conditions":628,"keywords":630,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":637,"completionDateStruct":639,"leadSponsor":641,"locationsCount":48},"100563747","generating-mucosal-immunity-after-influenza-infection-and-vaccination-in-lung-and-lymphoid-tissue-100563747","NCT06620185","GEneRating Mucosal Immunity After INfluenzA Infection and Vaccination in Lung and Lymphoid TissuE","A Two-arm, Non-randomised, Open-label Experimental Medicine Study to Compare Immune Responses Between Healthy Volunteers Aged 18-55years Receiving Either an Intranasal Live-attenuated Influenza Vaccine or Viral Challenge With GMP Influenza A\u002FBelgium\u002F4217\u002F2015 (H3N2)","GERMINATE","Inclusion Criteria:\n\n* Adults aged between 18-55 years inclusive\n* Sero-suitable as defined by a serum micro-neutralisation titre \\\u003C1:20\n* Female participant who is not of child-bearing potential as assessed by an investigator OR is willing and able to use contraception as described in the protocol\n* Male participants who are willing to use one of the contraception methods described in the protocol\n* In good health with no clinically significant medical conditions\n\nExclusion Criteria\n\n* History of clinically significant\u002Fcurrently active conditions;\n\n  * Cardiovascular, thromboembolic\u002Fcerebrovascular disease.\n  * Types of chronic respiratory disease in adulthood.\n  * Significant wheeze in the past\n  * Respiratory symptoms including wheeze, resulting in hospitalisation\n  * Known bronchial hyperactivity to viruses\n  * Diabetes mellitus\n  * Migraine with associated symptoms like hemiplegia\u002Fvision loss. Cluster headache\u002Fmigraine\u002Fprophylactic treatment for migraine.\n  * History of autoimmune disease\u002Fknown immunodeficiency of any cause\n  * Immunosuppression.\n  * Known coagulation disorder\u002Fanticoagulant therapy\n  * Psychiatric illness including participants with a history of depression and\u002For anxiety with associated psychiatric comorbidities\n  * Other major disease that, under the PI's discretion, could interfere with the participant completing the study.\n* Concurrent serious illness including history of malignancy that could interfere with the study or a participant completing the study.\n* Known IgA deficiency\u002Fimmotile cilia syndrome\u002FKartagener's syndrome\n* Significant abnormality altering the anatomy\u002Ffunction of the nose or nasopharynx, a clinically significant history of epistaxis within the last 3 months, nasal\u002Fsinus surgery within 6 months of Day 0, including nasopharyngeal malignancy, arterio-venous malformation, or undiagnosed nasopharyngeal mass\n* Inhaled bronchodilator\u002Finhaled steroid use within the last 12 months before Day 0\n* Acute upper respiratory tract infection in the past 6 weeks.\n* Receipt of systemic glucocorticoids (in a dose ≥ 5 mg prednisone daily or equivalent) within one month, or any other cytotoxic or immunosuppressive drug within 6 months before Day 0\n* Receipt of any vaccine within 30 days of Day -14\n* Any significant medical condition\u002Fprescribed drug, under the PI's discretion\n* Presence of cold-like symptoms and\u002For fever on Day -14 or Day 0.\n* Receipt of blood\u002Fblood products\u002Floss (including blood donations) of 550 mL or more of blood during the 3 months prior to Day -14.\n* Significant history\u002Fpresence of drug\u002Falcohol misuse by self-report.\n* Current use of drugs through nose inhalation or inhaled route including recreational drugs.\n* Regular smoking and\u002For vaping and\u002For using nicotine-containing products in the past 3 months OR \\>5 pack-year lifetime history by self-report (5 pack years is equivalent to one pack of 20 cigarettes per day for 5 years).\n* History of anaphylaxis and\u002For a history of severe allergic reaction or significant intolerance to any food\u002Fdrug, as assessed by the PI.\n* Clinically active rhinitis (including hay fever)\u002Fhistory of moderate to severe rhinitis\u002Fhistory of seasonal allergic rhinitis likely to be active at the time of inclusion into the study and\u002For requiring regular nasal corticosteroids on an at least weekly basis, within 30 days of enrolment.\n* Anyone with any of the following contraindications to receiving the Fluenz Tetra Vaccine:\n\n  * Allergy to gentamicin, gelatin or the other ingredients of the fluenz vaccine.","55 Years",{"count":625,"type":21},36,[24],"This experimental medicine study aims to compare immune responses in healthy adult volunteers aged 18-55 years against influenza vaccination and infection in the upper and lower respiratory tract, following administration of a live-attenuated influenza vaccine delivered by nasal spray versus influenza A (H3N2) viral challenge.",[629],"Influenza",[631,632,633,629,634],"LAIV","Challenge","Vaccine","Flu","2026-04-15",{"date":611,"type":40},{"date":638,"type":40},"2025-04-16",{"date":640,"type":21},"2026-07-31",{"name":46,"class":47},{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":647,"acronym":648,"eligibilityCriteria":649,"healthyVolunteers":12,"sex":650,"minAge":18,"maxAge":4,"enrollmentInfo":651,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":653,"conditions":654,"keywords":656,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":666,"lastUpdatePostDateStruct":667,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":48},"100613246","identifying-the-best-follow-up-approach-for-people-who-have-had-treatment-to-cure-newly-diagnosed-prostate-cancer-100613246","NCT07264088","Identifying the Best Follow up Approach for People Who Have Had Treatment to Cure Newly Diagnosed Prostate Cancer","The FOLLOW UP Study - a Natural Experiment Estimating the Clinical and Cost-effectiveness of Follow up Strategies After Curative Treatment for Prostate Cancer","FOLLOW-UP","Inclusion criteria:\n\nAll hospitals in England that provide radical prostatectomy or radical radiotherapy or focal therapy for prostate cancer and are identified by clinicians as receiving one of the four follow up strategies of interest will be eligible for inclusion in the study.\n\nIndividual patients satisfying the following criteria will be eligible for inclusion:\n\n* Having newly-diagnosed non-metastatic, clinically localised prostate cancer (ICD-10 code C61) in the Cancer Registry between 1 January 2018 and 31 December 2023;\n* Age 18 or over at diagnosis;\n* Completed primary curative treatment at an eligible hospital between 1 January 2019 and 31 December 2023 with either: radical radiotherapy +\u002F- hormones, or radical prostatectomy with curative intent +\u002F- lymphadenectomy, or focal therapy, in keeping with local practice;\n* Alive with no disease progression or metastasis 6 months after the date of completion of primary curative treatment.\n\nExclusion criteria:\n\n* Men who are treated for metastatic cancer; or receiving palliative prostate cancer care;\n* Men who have opted out of their data being used as part of national routine data sets will be excluded (https:\u002F\u002Fdigital.nhs.uk\u002Fservices\u002Fnational-data-opt-out).\n\nRecruitment to the survey component of the study will be limited to a sub-cohort of eligible participants that additionally meet the following criteria:\n\n* Alive;\n* Have achieved between three to four and a half years of follow up (from completion of initial curative treatment) during the survey period.","MALE",{"count":652,"type":21},100000,"Over 20,000 patients a year in the UK get surgery or radiotherapy to cure their prostate cancer. These men then undergo regular check-ups to manage potential side effects and see if cancer recurs so it can be treated quickly. The organisation of these check-ups varies across the country as it is not known which approach is best. The four different established approaches are (i) check-ups performed in hospital outpatients by the same team that provided treatment; (ii) patients seen regularly by their GP with hospital referral as necessary; (iii) planned shared care between general practice and hospital follow up; or (iv) patients supported to provide checks on themselves (self-care) and reaching out to a doctor or a nurse when required. This study will compare these options to establish which is best for patients and makes the best use of the NHS resources.",[655],"Prostate Cancer",[657,658,659,660,661,662,663,664,665],"prostate cancer","prostate cancer after curative treatment","prostate cancer follow up","propensity-matched cohort study","qualitative","discrete choice experiment","economic evaluation","routine data","patient survey","2026-04-13",{"date":668,"type":40},"2026-04-16",{"date":670,"type":21},"2026-10",{"date":672,"type":21},"2027-07",{"name":46,"class":47},{"id":675,"slug":676,"hasResults":12,"nctId":677,"briefTitle":678,"officialTitle":679,"acronym":680,"eligibilityCriteria":681,"healthyVolunteers":89,"sex":17,"minAge":682,"maxAge":224,"enrollmentInfo":683,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":684,"conditions":685,"keywords":689,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":666,"lastUpdatePostDateStruct":696,"startDateStruct":698,"completionDateStruct":700,"leadSponsor":702,"locationsCount":48},"100601572","using-multiomics-to-define-mechanisms-of-rhinovirus-induced-chronic-obstructive-pulmonary-disease-exacerbations-to-develop-novel-therapies-and-therapeutic-targets-100601572","NCT07112235","Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets","Using Multiomics to Define Mechanisms of RhinoVirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets","MRVCOPD","Inclusion Criteria for COPD subjects\n\n* Male or female sex\n* Age ≥40 years and ≤75 years at the time of signing the consent form\n* Medical history or clinical diagnosis of COPD\n* Significant smoking history, defined as:\n\n  * Cumulative smoking history of at least 20 pack years\n  * Permitted to currently use, or have history of use of, e-cigarettes\u002Fvapes\n* COPD spirometry criteria:\n\n  * Post bronchodilator FEV1 of \\\u003C80% and ≥50% predicted for age and height (equivalent to GOLD criteria stage 2 for 'Moderate' severity COPD9)\n  * Post-bronchodilator FEV1\u002FFVC ratio \\\u003C0.7\n  * β-agonist reversibility: an improvement of less than 12% predicted FEV1 and less than 200mL after 200 micrograms of salbutamol or equivalent short acting beta-2 agonist bronchodilator.\n* History of acute exacerbations of COPD as defined by the participant answering \"yes\" to the question: \"do your COPD symptoms get noticeably worse when you catch a cold?\"\n* Clinically stable with no COPD exacerbations within 8 weeks prior to enrolment\n* Permitted to take short and long-acting bronchodilators including beta agonists and muscarinic antagonist inhalers\n* Co-morbidity criteria:\n\n  * Permitted to have a past medical history of asthma, allergic rhinitis and seasonal rhinitis, but not currently active within 8 weeks prior to enrolment\n  * Absence of current or previous history of significant respiratory disease, other than COPD, asthma and allergic rhinitis\n* Permitted to have a positive skin test for atopy\n\nInclusion Criteria for non-smoking controls\n\n* Male or female sex\n* Age ≥ 40 years and ≤ 75 years at the time of signing the consent form\n* No history or clinical diagnosis of COPD\n* No significant smoking history, defined as:\n\n  * Less than 5 pack year cumulative smoking history\n  * Has not smoked or used e-cigarettes\u002Fvapes in the last 1 year\n* Controls spirometry criteria\n\n  * FEV1 of ≥80% predicted for age and height\n  * FEV1\u002FFVC ratio ≥0.7\n* Co-morbidity criteria:\n\n  * Permitted to have a past medical history of asthma, allergic rhinitis and seasonal rhinitis, but not currently active in the 8 weeks prior to enrolment\n  * Absence of current or previous history of significant respiratory disease, other than asthma and allergic rhinitis\n* Permitted to have a positive skin test for atopy.\n\nInclusion Criteria for smoking controls\n\n• Identical to non-smoking controls, with the exception of smoking history:\n\n* Cumulative smoking history of at least 20 pack years.\n* Permitted to currently use, or have history of use of, e-cigarettes\u002Fvapes\n\nExclusion Criteria:\n\n* Participants with other causes of chronic airflow limitation, including but not limited to:\n\n  * Bronchiectasis including cystic fibrosis\n  * Bronchiolitis obliterans\n  * Carcinoma of the bronchus\n  * Fibrosis such as tuberculosis (TB), idiopathic pulmonary fibrosis\n* Presence of any significant systemic disease, that in the opinion of the investigator would (a) make participation in the study unduly risky, or (b) significantly interfere with important outcomes being measured.\n\n  * For example, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric conditions.\n* Pregnant, planning to become pregnant, testing positive for pregnancy at the screening visit test, or nursing females during and within 30 days of treatment.\n* Treatment with oral, inhaled or nasal corticosteroids within 8 weeks prior to enrolment.\n* Treatment with antibiotics in the 8 weeks preceding enrolment.\n* Treatment with nasal medications, anti-leukotrienes, anti-histamine at the time of the study.\n* Presence (at screening) of serum rhinovirus-A16 neutralising antibodies in a titre \\>1:2.\n* Individuals with close contact to at risk patient group, including:\n\n  * Infants (less than 6 months);\n  * The extremely elderly or infirm;\n  * Pregnant and\u002For breastfeeding women;\n  * Patients with immunosuppression (e.g., human immunodeficiency virus (HIV), transplant recipients on anti-rejection medications, those undergoing chemo- or immuno-therapy).\n  * Other factors that in the opinion of the investigator are considered a risk.\n* Participation in other clinical research studies that, in the opinion of the investigator, would (a) make participation in the study unduly risky, or (b) significantly interfere with important outcomes being measured in this or other studies, or (c) present an unacceptable visit burden to the participant.","40 Years",{"count":272,"type":21},"The goal of this study is to examine exacerbations of chronic obstructive pulmonary disease (COPD) caused by a common cold virus called rhinovirus, to identify new treatments. Exacerbations are flare-ups of respiratory symptoms which are a major cause of ill health in people with COPD, and are most commonly caused by viruses.\n\nThe main questions the study aims to answer are:\n\n* What processes in the body occur in response to rhinovirus infection, and do the differences between people with COPD and healthy volunteers explain why people with COPD develop more severe illness and exacerbations?\n* Can treatments be identified that target these processes to reduce the severity and frequency of exacerbations in people with COPD?\n\nThe study will compare eligible participants with COPD to healthy volunteers, and will involve intentionally infecting each participant with rhinovirus in a controlled environment. They will undergo baseline investigations prior to infection including a first bronchoscopy. Post-infection each participant will undergo a range of tests, including a second bronchoscopy, to compare how processes in the body, and especially the lungs, differ between people who do and do not have COPD.",[686,687,688],"COPD (Chronic Obstructive Pulmonary Disease)","Rhinovirus Infection","Exacerbation of COPD",[690,691,692,693,694,695],"COPD","Chronic Obstructive Pulmonary Disease","Exacerbation","Multiomics","Rhinovirus","Viral challenge study",{"date":697,"type":40},"2026-04-14",{"date":699,"type":40},"2025-10-08",{"date":701,"type":21},"2027-03-31",{"name":46,"class":47},""]